Member Info for WaitingRoom

Chris. Priceless!

HH. I hope you leave your options open. Your posts are valuable to the board. Perhaps use the filter for a while; I often count to 10 (or more often 20) as an alternative. Maybe just observe and keep your powder dry for the big battles. Anyway, all the best on whatever you decide.

https://chrismaley.com/2019/11/19/the-four-horse****s-of-the-apocalypse/

HH. Just for info; and you probably know it. Stu’s offer is an example of CONCERN TROLLING, He is becoming very transparent now you have unravelled his strategy.

Excellent post Cyrox,

To all,

On the issue of buys and sells. There are often occasions where one can deduce a buy or sell on the basis of whether stamp duty has been paid.

There are a few 5000 pound buys that are marked as sells today, where you can see that someone has wanted to buy 5000 pounds of shares and the amount marked in the totals is 4966. Stamp duty is not included in the total. The buyer sees it, but we do not. It is very easy to infer that the 5000 includes the shares, the stamp duty and the fees; but it shows as 4966.

Similarly the day before when a clear 15,000 buy was marked as indeterminate. However, it was a clear buy based on the same logic.

Happy to hold tightly until we re-rate. The banter continues to amuse.

Stu….it is ‘INTO the beginning’ not to the beginning.

But I suspect you knew that

Https://www.voxmarkets.co.uk/articles/traders-cafe-with-zak-mir-vladislav-sandler-ceo-hemogenyx-pharmaceuticals-8f9960f/

A year later…

Is this his ‘Annus mirabilis’?

yes, i have reviewed. i read back through the history. not applicable to this.

um… btw…25 years developing x-rays and neutron imaging detectors

getting really ****ed off with you guys that have no experience of fda submissions. been there on the journey with companies like siemens medical.

nothing is ever straightforward, but you don’t get this far without ensuring your ducks are in a row.

hopefully you are fully invested and can now sit back and enjoy the ride. if you are not then i’m playing the worlds smallest violin for you.

enjoy your weekend.

Where there’s muck there’s brass!

Stu.

Re: Polx

Another disingenuous post. I would filter you, but you need to be called out on this every time you try to introduce FUD

Will check it out

Thanks

Stu

Why not liven up the discussion and suggest when you think it is most likely to fail.

You are always ready to pick at other people’s suggestions or even the actual RNS. Why not go out on a limb…no guessing though.

If you really think this is destined to fail why don’t you just clear off.

Happy Friday everyone, and anchors aweigh.

And is being disingenuous because the ‘minimize’ statement was in the narrative from the Chairman in the annual report, and not in the IND submission RNS.

It is reassuring that they have the feedback loop with this particular division of the FDA, in order to avoid any last minute glitches.

Stu,

If it cures then will be content with whatever the SP is.

This is not a life defining project for me. My first wife died from leukemia and I just want to see these guys succeed.

GLA

I am sure the FDA are eagerly awaiting the outcome of you wager....

All I want is for the company to succeed either in June, or August.

It would be great to translate this six figure investment into a seven figure investment.

"This application follows the Company's successful work on manufacturability, quality, safety and other key parts of the development of HEMO-CAR-T. Once the clinical investigation plan proposed in the IND submission has been cleared to proceed by the FDA, the Company plans to initiate a Phase I clinical trial of HEMO-CAR-T."

I thought that the wording was very affirmative that they had satisfied the criteria; my questions would be related to the time delta to commencement of trials.

"We have been particularly concerned to cover all aspects in preparing the IND documentation so as to minimise any possible delays and questions that may arise from its review by the US Food and Drug Administration ("FDA"). "

"We received constructive early feedback and guidance from a "pre-IND submission" to the FDA which have helped to shape the final submission, along with advice from our Medical Director and a committee of "Key Opinion Leaders" who are experts in the treatment of leukaemias, as well as the design and conduct of clinical trials."

This is from the annual report. So they have been in communication with the FDA in order to get the submission right first time, and to avoid steps that would lead to unnecessary or unwanted delays.

There may, or may not be further delays; who knows. They clearly did extra work on the manufacture and safety aspects before eventual submission.

I suggest that if they felt comfortable with submission, and subsequent release of share options, then they were confident in the quality of the submission.

isn't that the best you can ask of them?

Good call Blastoid

All shares and options get consolidated. Market cap remains the same. Maybe a little more volatile because of churn; saw that with HZM.

It does help to take it away from penny share classification- some institutions won’t touch penny shares.

Ditto low market caps…this is the real challenge, as VS will make better headway if he can get this above $100m

It’s a pretty good stab at it. As he is taxed in the US, then it will be much more complicated. He may have to take the hit on exercise, as shares held under one year are treated as income rather than capital. On the other hand the share scheme might be through the LLC in a US scheme. It’s not simple by any means.

Hopefully he has good advisors; they are worth their weight in gold.